Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension safety study of dazodalibep in Sjogren's syndrome
jRCT2061250001Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Nov 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of dazodalibep in Sjögren's syndrome, sponsored by Amgen. Primary endpoints: Incidence of treatment-emergent adverse events (TEAEs), Incidence of treatment-emergent serious adverse events (TESAEs) and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
dazodalibep
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on jRCT2061250001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250001.